AstraZeneca: AstraZeneca & Daiichi Sankyo's Enhertu gets EU approval to treat patients with HRpositive, HER2low or HER2ultralow metastatic breast cancer following at least one endocrine therapy

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone